May Newsletter for Chinese IVD companies —— Mindray, Hybribio and USCI

Mindray plans to distribute a cash dividend of 4.23 billion CNY

2022CACLP Booth No.: A4-2001

On May 11, Mindray announced that the company would implement the equity distribution in 2021 and distribute cash dividends of CNY 35.00 plus tax to all shareholders for every 10 shares. The equity registration date is May 18. As of the date of this announcement, the total share capital of the company is 1,212,441,394 shares, and the number of shares in the company's special securities repurchase account is 3,048,662 shares. According to the provisions of the company law, this part of the repurchased shares do not enjoy the right to participate in this profit distribution. Based on the total share capital excluding 1,209,392,732 shares repurchased in the special securities account for repurchase, it is proposed to distribute a total cash dividend of 4,232,874,562.00 CNY plus tax.

Hybribio plans to invest 1.512 billion CNY to build Medical Science Park

2022CACLP Booth No.: A1-2609

On May 11, Hybribio announced that it plans to invest in the construction of Hybribio Medical Science Park. The total investment of the project is expected to be about 1.512 billion CNY and the required land is about 235 mu (1mu≈666.66㎡). The planned construction contents of the project include the production base of high-end biomedical experimental consumables and in vitro diagnostic raw materials, the production base of COVID-19 epidemic prevention testing supporting reagents, the research and development intelligent manufacturing base of biological instruments, the production base of new disinfection and protective articles, the production base of packaging materials, Hybribio innovation Research Center, inspection and nursing and other medical personnel training and high-end academic exchange center Biotechnology industry chain enterprise introduction and incubation service base and other production and living related supporting facilities.

USCI completed hundreds of millions of CNY of financing and accelerated to lead the early screening track of liquid biopsy and women's health

On May 11, USCI announced that it had recently completed a new round of equity financing. This round was led by Decheng capital, with the participation of Infinity Equityl, Health-100 Industry Fund, Beijing Zhongguancun Science City, Shandong Hongqiao Capital, Hongzhou Capital and Hengjia Capital, totaling hundreds of millions of CNY. Previously, USCI medicine has obtained the strategic investment of BGI and the early investment of Xianfeng Qiyun, CITIC Guoan and other investment institutions. The funds raised in this round will be mainly used for the R & D, registration and industrialization of USCI source innovative instruments and reagents, accelerate the layout and expansion of the national marketing network, and further consolidate USCI` s leading position in technological innovation and industrial incubation in the field of liquid biopsy and women's health early screening.

Founded in 2015, as a national high-tech industrial unit and a national specialized "Little Giant" enterprise (the first batch and the first year), USCI medicine has successively undertaken the special project for the prevention and control of reproductive health and major birth defects in the 13th Five Year Plan of the Ministry of Science and Technology and the multi center R & D project of tumor liquid biopsy.